Free tool
FAERS Monitor: Lytgobi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214801 or its brand name (Lytgobi, Futibatinib). Reports on generic versions are filed under their own applications.
Reports
222
Serious
152
68% of reports
Hospitalization
71
Death reported
42
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea39
- hyperphosphataemia36
- death32
- disease progression31
- fatigue28
- nausea26
- dry mouth24
- off label use20
- vomiting18
- onychomadesis17
- blood phosphorus increased16
- constipation16
- dry eye16
- neuropathy peripheral16
- alopecia15
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 3 |
| 2022 | 14 |
| 2023 | 50 |
| 2024 | 59 |
| 2025 | 57 |
| 2026 | 39 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,937 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperphosphataemiaSignal | 36 | 1613.5 | 1192.9 | 55,474 |
| blood phosphorus increasedSignal | 16 | 558.5 | 347.8 | 8,307 |
| onychomadesisSignal | 17 | 385.3 | 243.8 | 6,114 |
| dry eyeSignal | 16 | 30.4 | 18.9 | 427 |
| dry mouthSignal | 24 | 28.0 | 19.2 | 601 |
| disease progressionSignal | 31 | 24.8 | 17.9 | 689 |
| neuropathy peripheralSignal | 16 | 15.9 | 9.9 | 210 |
| alopeciaSignal | 15 | 7.2 | 4.4 | 75 |
| constipationSignal | 16 | 7.0 | 4.3 | 76 |
| diarrhoeaSignal | 39 | 5.7 | 4.3 | 152 |
| vomitingSignal | 18 | 3.6 | 2.3 | 32 |
| deathSignal | 32 | 3.5 | 2.6 | 58 |
| fatigueSignal | 28 | 3.4 | 2.4 | 47 |
| nauseaSignal | 26 | 3.1 | 2.2 | 37 |
| off label useSignal | 20 | 2.2 | 1.4 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.